
Figure 1







Figure 2



2/15
SUBSTITUTE SHEET (RULE 26)

Figure 3






Figure 4




Compound concentration (µM)

4/15
SUBSTITUTE SHEET (RULE 26)


FIGURE 5





5/15
SUBSTITUTE SHEET (RULE 26)


FIGURE 5 (continued)



6/15
SUBSTITUTE SHEET (RULE 26)

FIGURE 5 (continued)


HCT116-e28



Tumor Size (mm⁻³)


7/15
SUBSTITUTE SHEET (RULE 26)

FIGURE 5 (continued)




8/15
SUBSTITUTE SHEET (RULE 26)

FIGURE 5 (continued)




9/15
SUBSTITUTE SHEET (RULE 26)

FIGURE 5 (continued)



10/15
SUBSTITUTE SHEET (RULE 26)


FIGURE 5 (continued)



11/15
SUBSTITUTE SHEET (RULE 26)

Figure 6

(a)




(b)

| Treatment Vehicle | Dose (mg/Kg) | Max % BW loss (day) | PR | CR | Cures | Max TGI (day) | LCK (Td:2.2) |
|----------------------|-----------------|---------------------------|--------|--------|-------|------------------|-----------------|
| Cytoxan (QODx5) | 100 (ip) | -8.5 (16) | 9 | 1 | 0 | 98.5 (19) | 3.47 |
| A37 (QDx10) | 60 (iv) | -23.6 (12) | 9 | 1 | 3 | 98.5 (19) | 3.64 |
| A37 (QDx10) | 50 (iv) | -14 (16) | 5 | 1 | 0 | 94.5 (16) | 1.73 |
| A37 (QDx10) | 40 (iv) | -9.7(16) | 1 | 0 | 0 | 82.5 (14) | 1.23 |

12/15
SUBSTITUTE SHEET (RULE 26)

Figure 7

(a)




(b)

| Treatment Vehicle | Dose (mg/Kg) | Max % BW loss (day) | PR | CR | Cures | Max TGI (day) | LCK (Td:2.2) |
|----------------------|---------------------|---------------------------|--------|--------|-------|------------------|-----------------|
| Cytoxan (QDx5) | 100 (ip) | | 5 | 0 | 0 | 96 (25) | 3.47 |
| A37 (QDx5/2/5) | 50 (iv) | -5.7 (15) | 8. | 0 | 1 | 98 (18) | 1.69 |
| A37 (QDx5/2/5) | 40 (iv) | | 4 | 1 | 0 | 89 (15) | 1.21 |
| A37 (QDx5/2/5) | 30 (iv) | | 1 | 0 | 0 | 76 (15) | 0.29 |

13/15
SUBSTITUTE SHEET (RULE 26)

Figure 8



(a)

(b)

| Treatment . | Dose (mg/Kg) | Toxic Deaths 0 | PR | CR | Cures | Max TGI (day) | LCK (Td:2.2) |
|-------------------|-----------------|----------------------|--------|----|-------|------------------|-----------------|
| Cytoxan (QDx5) | 100 (ip) | 0 | 3 | 7 | 0 | 99 (15) | 4.4 |
| B16 (QDx10) | 70 (iv) | 2 | 0 . | 8 | 5 | 99 (15) | >4.4 |
| B16 (QDx10) | 50 (iv) | 0 | 1 | 9 | 7 | 99 (15) | >4.4 |
| B16 (QDx10) | 30 (iv) | 0 | 2 | 1 | 1 | 79 (14) | 1.7 |

14/15
SUBSTITUTE SHEET (RULE 26)

Figure 9

